Five Prime, Lonza, Kyowa Hakko Kirin deal

Five Prime received rights from Lonza and Kyowa's BioWa Inc. subsidiary to apply the Potelligent CHOK1SV cell line technology to antibodies in Five Prime's cancer pipeline. Potelligent CHOK1SV cell l...